A year after Warren Buffett’s Berkshire Hathaway took a contrarian $1.6 billion stake in UnitedHealth Group (UNH), the health insurance giant has delivered a first-quarter earnings beat that strongly vindicates the move — and once again underlines the Oracle of Omaha’s flair for buying quality companies when they are temporarily out of favor.
UnitedHealth reported adjusted earnings per share of $7.23 for the quarter, far exceeding the $6.57 analysts had forecast. Revenue rose to $111.7 billion, also ahead of the $109.6 billion consensus estimate. The company raised its full-year profit outlook, sending the stock higher.
The standout number was the medical cost ratio — the share of premiums paid out for medical claims. It fell to 83.9% from 84.8% a year ago, comfortably below the 85.5% Wall Street had penciled in. That improvement came despite no easing in the actual demand for healthcare. Tim Noel, CEO of the UnitedHealthcare unit, told analysts that utilization remains at the elevated levels seen since 2025. Instead of waiting for cost pressures to fade, the insurer simply raised premiums — a rate-hike plan announced last year was pushed through forcefully, allowing higher premium income to more than cover the still-surging claims. CEO Stephen Hemsley called the quarter an early chapter in a genuine turnaround.
The results validate the logic behind Buffett’s original investment. Insurance, whether in the property-and-casualty business that forms Berkshire’s core or in health coverage, operates on a simple principle: when claims eat into profits, carriers can almost always restore margins by repricing policies. Pricing power is the ultimate moat, and last year, when UnitedHealth was hammered by a leadership shake-up, a Department of Justice probe, and a 35% annual share-price plunge, Buffett bet that the damage was temporary rather than structural. The Q1 numbers suggest that call was right.
The episode also highlights Buffett’s patience. Earlier this year, the Centers for Medicare & Medicaid Services initially proposed deeply disappointing Medicare Advantage rates for 2027, unsettling the market. Berkshire held its ground. CMS ultimately revised the rates significantly higher in the final rule, handing Buffett another payoff for staying calm.
Still, the story is not without lingering risks. Senator Chuck Grassley has been investigating whether UnitedHealth used aggressive tactics to inflate risk-adjustment scores in its Medicare Advantage business — making patients appear sicker in order to secure larger payments from the government. A report stemming from that probe accused the company of systematic manipulation. Should the investigation result in tighter regulation or financial penalties, the very playbook that is now driving earnings — premium increases paired with coding optimization — could come under pressure.
For now, UnitedHealth’s quarterly report is a clear win for the company and for its most famous investor. The episode reinforces a long-standing Buffett lesson: buy great businesses when they are on sale, and don’t let short-term noise obscure durable competitive advantages. Yet with regulatory clouds still overhead, the stock’s recent rally may already be pricing in a rosy scenario that has not fully materialized. Whether this turnaround marks the start of a sustained recovery or merely a powerful snapback that warrants caution remains an open question — even if the early evidence is squarely in Buffett’s favor.
